Need professional-grade analysis? Visit stockanalysis.com
$1.60B
N/A
N/A
N/A
Palvella Therapeutics, Inc (PVLA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $130.65, up 0.49% from the previous close.
Over the past year, PVLA has traded between a low of $20.51 and a high of $148.34. The stock has gained 391.9% over this period. It is currently 11.9% below its 52-week high.
Palvella Therapeutics, Inc has a market capitalization of $1.60B.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Side-by-side comparison against top Healthcare peers.